About Evommune
Evommune is a publicly listed company based in Sacramento (United States) founded in 2020 by Luis Pena. Developer of therapeutic options for chronic inflammatory disorders. Evommune has raised $275.5 million across 6 funding rounds from investors including Beiersdorf, EQT and Marshall Wace. Its chief executive, as recorded, is Luis Pena. Evommune offers products and services including EVO756 and EVO301. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is Evommune, Inc. Its competitors include Aclaris Therapeutics, Incyte and Escient Pharmaceuticals; 2 of its 3 listed competitors have raised funding.
Company details
Evommune was founded in 2020 and is based in Sacramento, United States. Focus is placed on the biotechnology sector, where therapeutic candidates for chronic inflammatory disorders are developed. The pipeline includes options targeting IL-37 for rosacea and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCθ for atopic dermatitis. A tissue-based screening platform is utilized to support drug development for these conditions.
- Headquarters Sacramento, United States
- Founders Luis Pena
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website evommune.com
- Social LinkedIn
- Legal Name Evommune, Inc.
- Total Equity Funding$275.5M (USD)
in 6 rounds
- Latest Funding Round$125M (USD), Post-IPO
Feb 2026
- InvestorsBeiersdorf
& 18 more
Products & Services of Evommune
Evommune offers a comprehensive portfolio of products and services, including EVO756 and EVO301.
MRGPRX2 antagonist for treating chronic spontaneous urticaria.
IL-18 targeted therapy for atopic dermatitis management.
Funding Insights of Evommune
Evommune has successfully raised a total of $275.5M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $125 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $275.5M
- Total Rounds 6
- Last Round Post-IPO — $125M
- First Round $12.5M
(Oct 2020)
- Investors Count 19
All 6 funding rounds of Evommune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $125M | Post-IPO | – | – | – |
| Oct 2024 | $115M | Series C | – | RA Capital Management, Sectoral | |
| Jun 2023 | $7.5M | Series B | – | Verition Fund Management | – |
| Mar 2023 | $57.5M | Series B | – | Arix Bioscience, EQT | |
| Aug 2021 | $83M | Series A | – | Andera Partners | |
| Oct 2020 | $12.5M | Seed | – | Pivotal bioVenture Partners | – |
19 investors in total: 19 institutional.
Investors in Evommune
Evommune has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Beiersdorf, EQT and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Multistage investments are directed toward technology, healthcare, and climate sectors. | b.capital | Manhattan Beach, United States | ||
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Private equity investments are directed toward the healthcare sector. | avego.com | Alpharetta, United States | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Investments are focused on innovations in women's health. | 2019 | femhealthventures.com | ||
A global healthcare investment firm supporting innovative therapeutic companies. | 2017 | pivotallifesciences.com | San Francisco, United States | |
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France |
Investor details for Evommune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evommune
36 people are tracked at Evommune (15 in leadership, 14 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Luis Pena | Co-Founder & CEO | Leadership |
Eugene A. Bauer | Chief Medical Officer | Leadership |
Greg Moss | Chief Corporate Strategy & Legal Officer | Leadership |
Jeegar Patel | Chief Scientific Officer | Leadership |
Sam Chi | Vice President, Commercial And Portfolio Planning | Leadership |
Derek Kuwahara, PharmD, MS, MBA | Senior Director Business Development | Leadership |
Rachel Hunter | Senior Director of Human Resources | Leadership |
Mark Jackson | Vice President of Clinical Development | Leadership |
Kyle Carver | CFO | Leadership |
Luis Peña | President & CEO | Leadership |
Julia Kong | Director, Supply Chain | Leadership |
Alex Brehm, CPA | Controller, Senior Director Finance | Leadership |
Lauren Krusius | Executive Director, Corporate Strategy And Portfolio Management | Leadership |
Polina Bukshpun | Senior Director, Clinical Operations | Leadership |
Andrea S. Kim, PhD, MBA, DABT | Executive Director, Nonclinical Development | Leadership |
Stephen J. Galli | Scientific Advisor | Board & advisors |
David E. Cohen | Director | Board & advisors |
Benjamin F. McGraw III | Director | Board & advisors |
Brian Berman | Scientific Advisor | Board & advisors |
Emma Guttman-Yassky | Scientific Advisor | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Evommune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Evommune
Evommune is a publicly listed company on the NYSE with ticker symbol EVMN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Nov 2025
- Listed onNYSE: EVMN
- Listed entityEvommune, Inc.
- Exchange sectorHealth technology
- ISINUS30054Y1073
- Share price$5.88 (-2.81% on the day) · 2026-10-13
- Market capitalisation$213.4M
- EPS (diluted, trailing year)$-2.83
- Volume (last session)805,294
Timeline of Evommune
4 dated milestones of Evommune across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Evommune is founded.
- Funding First funding round of $12.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $125.0M.
Competitors of Evommune
Evommune has 3 listed competitors in our database, 2 of them funded. They include Aclaris Therapeutics, Incyte and Escient Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. | ||
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. |
Detailed competitors of Evommune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evommune
The website of Evommune (evommune.com) receives about 8.3K visits a month.
- Monthly visits8.3K
▼ 16.7% vs previous month
Websites whose visitors overlap most with Evommune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| diedremoire.com | 100% | #2,516,604 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Evommune (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evommune
Complete news archive for Evommune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evommune
Evommune was founded in 2020.
Evommune is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Luis Pena is the CEO of Evommune, as recorded in our data. They have also founded this company.
Evommune is a funded company, having raised a total of $275.5M across 6 funding rounds to date. The company's 1st funding round was a Seed of $12.5M, raised on Oct 2020.
Evommune was founded in 2020 and is based in Sacramento, United States. Focus is placed on the biotechnology sector, where therapeutic candidates for chronic inflammatory disorders are developed. The pipeline includes options targeting IL-37 for rosacea and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCθ for atopic dermatitis. A tissue-based screening platform is utilized to support drug development for these conditions.
Evommune's top competitors include Escient Pharmaceuticals, Aclaris Therapeutics and Incyte.
Evommune offers EVO756 and EVO301.
Yes, Evommune is publicly traded on NYSE under the ticker symbol EVMN.
Evommune has 19 investors. Key investors include Beiersdorf, EQT, Marshall Wace, RTW Investments, and RA Capital.
Evommune operates through Evommune, Inc..